The PD‐L1 expression of tumor tissue may represent a predictive biomarker to ICI immunotherapies and the persistence of PD‐L1 positive tumor tissue in this patient after immunotherapy resistance might reflect a mechanism of immunotherapy escape. This evidence concerns the gene CD274 and neoplasm.